Answers are grounded in this paper and cite their sources.
With the move towards more 'outcome' and 'value'-based treatment regimensincreasingly tailored for the individual patientthere is growing pressure on healthcare systems and the pharmaceutical sector to collaborate and co-develop innovative models of care and medication. This paper focuses on the impact disruptive digital technologies may have on the UK Pharma/National Health Service (NHS) ecosystem, and is set within the boundaries of treating chronic diseases. A comprehensive generic model for designing more 'connected' value networks is developed, and validated by an expert panel in the specific case of type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Burge et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: